Deferred Tax Assets, Valuation Allowance of CytomX Therapeutics, Inc. from 31 Dec 2013 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CytomX Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2024.
  • CytomX Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $162,110,000, a 7.6% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

CytomX Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $162,110,000 -$13,344,000 -7.6% 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q4 2023 $175,454,000 +$9,417,000 +5.7% 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q4 2022 $166,037,000 +$22,682,000 +16% 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q4 2021 $143,355,000 +$24,816,000 +21% 31 Dec 2021 10-K 27 Mar 2023 2022 FY
Q4 2020 $118,539,000 +$9,365,000 +8.6% 31 Dec 2020 10-K/A 27 Mar 2023 2021 FY
Q4 2019 $109,174,000 +$22,708,000 +26% 31 Dec 2019 10-K 24 Feb 2021 2020 FY
Q4 2018 $86,466,000 +$35,675,000 +70% 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q4 2017 $50,791,000 +$4,654,000 +10% 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q4 2016 $46,137,000 +$21,094,000 +84% 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q4 2015 $25,043,000 -$969,000 -3.7% 31 Dec 2015 10-K 07 Mar 2018 2017 FY
Q4 2014 $26,012,000 +$10,882,000 +72% 31 Dec 2014 10-K 02 Mar 2017 2016 FY
Q4 2013 $15,130,000 31 Dec 2013 10-K 07 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.